Yu Fengqiang, Liang Mingqiang, Wu Weidong, Huang Yu, Zheng Jiantao, Zheng Bin, Chen Chun
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Fujian Provincial Key Laboratory of Cardiothoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Front Oncol. 2021 Jan 26;10:628608. doi: 10.3389/fonc.2020.628608. eCollection 2020.
The role played by long noncoding RNA GCC2-AS1 in primary malignant tumors remains poorly understood. This study aimed to determine the expression levels and evaluate the clinical significance and biological effects of GCC2-AS1 in lung adenocarcinoma (LUAD).
We used data obtained from tissue samples and the TCGA database to determine the levels of GCC2-AS1 expression LUAD patients, and the prognostic value of those levels. Functional experiments were performed to investigate the effect of GCC2-AS1 on LUAD cells. Genes that were differentially expressed in GCC2-AS1-low and -high groups were analyzed by an enrichment analysis. Additionally, a nomogram model was created and subgroup analyses were performed to further determine the prognostic value of GCC2-AS1 in LUAD.
GCC2-AS1 expression was significantly upregulated in lung adenocarcinoma tissues as compared with normal tissues. Depletion of GCC2-AS1 inhibited the proliferation and invasion of LUAD cells . An elevated level of GCC2-AS1 was strongly correlated with shorter overall survival time and was identified as an independent prognostic marker for LUAD patients. Enrichment analyses conducted using GO, KEGG, and GSEA databases were performed to identify biological pathways that might involve GCC2-AS1. Several subgroups were found to have a significant prognostic value for patients in the GCC2-AS1-low and -high groups.
Our findings suggest that GCC2-AS1 can serve as a diagnostic and prognostic biomarker for LUAD patients.
长链非编码RNA GCC2-AS1在原发性恶性肿瘤中所起的作用仍知之甚少。本研究旨在确定GCC2-AS1在肺腺癌(LUAD)中的表达水平,并评估其临床意义和生物学效应。
我们使用从组织样本和TCGA数据库获得的数据来确定LUAD患者中GCC2-AS1的表达水平及其预后价值。进行功能实验以研究GCC2-AS1对LUAD细胞的影响。通过富集分析对在GCC2-AS1低表达和高表达组中差异表达的基因进行分析。此外,创建了列线图模型并进行亚组分析,以进一步确定GCC2-AS1在LUAD中的预后价值。
与正常组织相比,肺腺癌组织中GCC2-AS1表达显著上调。GCC2-AS1的缺失抑制了LUAD细胞的增殖和侵袭。GCC2-AS1水平升高与总生存时间缩短密切相关,并被确定为LUAD患者的独立预后标志物。使用GO、KEGG和GSEA数据库进行富集分析,以确定可能涉及GCC2-AS1的生物学途径。发现几个亚组对GCC2-AS1低表达和高表达组的患者具有显著的预后价值。
我们的研究结果表明,GCC2-AS1可作为LUAD患者的诊断和预后生物标志物。